Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310490 · ClinicalTrials.gov registry record · NA
DA-13-007 Versus Sculptra for the Treatment of Nasolabial Folds Wrinkles
A NA study of Face; Atrophy, sponsored by DermAvance.
- Completed
- Registry status
- NA
- Development phase
- 161
- Enrollment target
- 4
- Study locations
NCT02310490: Completed NA study of Face; Atrophy, sponsored by DermAvance.
NCT02310490 is a NA study of Face; Atrophy that has completed, run by DermAvance. The registered enrollment target is 161 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02310490, a NA study of Face; Atrophy, has completed, sponsored by DermAvance.
- COMPLETED
- Registry status
- NA
- Development phase
- 161 participants
- Enrollment target
- 4
- Study locations
Study Summary
Study DA-13-007 is a randomized, evaluator-blinded, within subject (split face) multicenter clinical study of DA-13-007l (Injectable poly-l-lactic acid) compared to SCULPTRA in the treatment of nasolabial fold wrinkles. Qualifying subjects will be randomized to receive DA-13-007l and SCULPTRA on either the right or left side of the face.
Primary Outcome
To evaluate the efficacy of treatment versus the comparator in a non-inferiority statistical model using a 5-grade WSRS (wrinkle severity rating scale) score and a rating by an independent evaluator
Conditions Studied
Interventions
- DEVICE DA-13-007 right with left side Sculptra left side
- DEVICE DA-13-007 left with left side Sculptra right side
Study Locations (4)
Florida
- Bay Area Dermatology - Bradenton
- Miami Skin Institute - Coral Gables
Indiana
- Laser & Skin Surgery Center of Indiana - Carmel
Washington
- PCR - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-12 |
| Phase | NA |
What the finished NCT02310490 record still lists
NCT02310490 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Face; Atrophy appearing as the primary indexed condition, and to 2 interventions - of which DA-13-007 right with left side Sculptra left side is the first listed.
NCT02310490 reports a single indexed study location in Florida, Indiana, Washington.
Frequently Asked Questions
What is clinical trial NCT02310490 about?
NCT02310490 is a clinical study titled "DA-13-007 Versus Sculptra for the Treatment of Nasolabial Folds Wrinkles". Study DA-13-007 is a randomized, evaluator-blinded, within subject (split face) multicenter clinical study of DA-13-007l (Injectable poly-l-lactic acid) compared to SCULPTRA in the treatment of nasolabial fold wrinkles. Qualifying subjects will be randomized to receive DA-13-007l and SCULPTRA on eit...
What is the current status of trial NCT02310490?
This trial is currently completed. It is a NA study. The enrollment target is 161 participants. The study started on 2015-01. Estimated completion is 2018-12.
What conditions does trial NCT02310490 study?
This clinical trial studies the following conditions: Face; Atrophy.
What interventions are being tested in trial NCT02310490?
The interventions under investigation include: DA-13-007 right with left side Sculptra left side (DEVICE), DA-13-007 left with left side Sculptra right side (DEVICE).
Who is sponsoring clinical trial NCT02310490?
This trial is sponsored by DermAvance, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02310490 being conducted?
This trial has 4 study locations across Florida, Indiana, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02310490's enrollment target sits among peer trials
161 628th of 2000 higher than 1,373 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia